© Reuters. FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid/File Photo
(Reuters) – Johnson & Johnson (NYSE:) said on Monday John Reed will take the role of executive vice president of pharmaceuticals, research and development, effective April 3.
Reed, 64, will replace William Hait, who was appointed the interim head of the unit in August 2022.
Reed has previously served in executive positions for drugmakers Sanofi (NASDAQ:) SA and Roche Holding AG (OTC:).
Be the first to comment